Literature DB >> 28988399

Control of HIV infection by IFN-α: implications for latency and a cure.

Nollaig M Bourke1,2, Silvia Napoletano3, Ciaran Bannan3,4, Suaad Ahmed3, Colm Bergin4, Áine McKnight5, Nigel J Stevenson6.   

Abstract

Viral infections, including HIV, trigger the production of type I interferons (IFNs), which in turn, activate a signalling cascade that ultimately culminates with the expression of anti-viral proteins. Mounting evidence suggests that type I IFNs, in particular IFN-α, play a pivotal role in limiting acute HIV infection. Highly active anti-retroviral treatment reduces viral load and increases life expectancy in HIV positive patients; however, it fails to fully eliminate latent HIV reservoirs. To revisit HIV as a curable disease, this article reviews a body of literature that highlights type I IFNs as mediators in the control of HIV infection, with particular focus on the anti-HIV restriction factors induced and/or activated by IFN-α. In addition, we discuss the relevance of type I IFN treatment in the context of HIV latency reversal, novel therapeutic intervention strategies and the potential for full HIV clearance.

Entities:  

Keywords:  Anti-viral; Cure; HIV; Interferon; JAK/STAT; Latency

Mesh:

Substances:

Year:  2017        PMID: 28988399     DOI: 10.1007/s00018-017-2652-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  96 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 2.  SAMHD1 host restriction factor: a link with innate immune sensing of retrovirus infection.

Authors:  Alexandre Sze; David Olagnier; Rongtuan Lin; Julien van Grevenynghe; John Hiscott
Journal:  J Mol Biol       Date:  2013-10-23       Impact factor: 5.469

3.  Recruitment and dynamics of proteasome association with rhTRIM5α cytoplasmic complexes during HIV-1 infection.

Authors:  Cindy M Danielson; Gianguido C Cianci; Thomas J Hope
Journal:  Traffic       Date:  2012-06-19       Impact factor: 6.215

4.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.

Authors:  Caroline Goujon; Michael H Malim
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

6.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

7.  Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection.

Authors:  Shamman Sewram; Ravesh Singh; Emil Kormuth; Lise Werner; Koleka Mlisana; S S Abdool Karim; Thumbi Ndung'u
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

8.  Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression.

Authors:  Michelina Nascimbeni; Leïla Perié; Laurent Chorro; Seckou Diocou; Louis Kreitmann; Stéphanie Louis; Laurent Garderet; Bettina Fabiani; Anne Berger; Jürgen Schmitz; Jean-Pierre Marie; Thierry Jo Molina; Jérôme Pacanowski; Jean-Paul Viard; Eric Oksenhendler; Stéphanie Beq; Orly Abehsira-Amar; Rémi Cheynier; Anne Hosmalin
Journal:  Blood       Date:  2009-04-14       Impact factor: 22.113

9.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

Review 10.  Interferon-alpha, immune activation and immune dysfunction in treated HIV infection.

Authors:  Lilian Cha; Cassandra M Berry; David Nolan; Allison Castley; Sonia Fernandez; Martyn A French
Journal:  Clin Transl Immunology       Date:  2014-02-28
View more
  5 in total

Review 1.  The role of IFN-γ production during retroviral infections: an important cytokine involved in chronic inflammation and pathogenesis.

Authors:  Patrícia Azevedo Soares Cordeiro; Tatiane Assone; Gabriela Prates; Marcia Regina Martinez Tedeschi; Luiz Augusto Marcondes Fonseca; Jorge Casseb
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2022-09-30       Impact factor: 2.169

2.  Identification of Latent Diagnostic Biomarkers and Biological Pathways in Dermatomyositis Based on WGCNA.

Authors:  Shaxi Ouyang; Yifang Liu; Changjuan Xiao; Qinghua Zeng; Xun Luo; Xiaofang Hu; Shuoshan Xie
Journal:  J Oncol       Date:  2021-12-30       Impact factor: 4.375

3.  MX2 Viral Substrate Breadth and Inhibitory Activity Are Regulated by Protein Phosphorylation.

Authors:  Gilberto Betancor; Madeleine Bangham; Jun Ki Jeon; Kanisha Shah; Steven Lynham; Jose M Jimenez-Guardeño; Michael H Malim
Journal:  mBio       Date:  2022-07-26       Impact factor: 7.786

4.  HIV-1 Promotes the Degradation of Components of the Type 1 IFN JAK/STAT Pathway and Blocks Anti-viral ISG Induction.

Authors:  Siobhan Gargan; Suaad Ahmed; Rebecca Mahony; Ciaran Bannan; Silvia Napoletano; Cliona O'Farrelly; Persephone Borrow; Colm Bergin; Nigel J Stevenson
Journal:  EBioMedicine       Date:  2018-03-09       Impact factor: 8.143

Review 5.  The Role of Dendritic Cells During Infections Caused by Highly Prevalent Viruses.

Authors:  Jorge A Soto; Nicolas M S Gálvez; Catalina A Andrade; Gaspar A Pacheco; Karen Bohmwald; Roslye V Berrios; Susan M Bueno; Alexis M Kalergis
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.